LMR Partners LLP acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the third quarter, HoldingsChannel.com reports. The fund acquired 33,678 shares of the financial services provider’s stock, valued at approximately $4,904,000.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Blue Fin Capital Inc. boosted its stake in iShares Biotechnology ETF by 0.7% during the second quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after acquiring an additional 74 shares in the last quarter. Security National Bank of SO Dak lifted its stake in shares of iShares Biotechnology ETF by 0.7% in the second quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock valued at $1,436,000 after buying an additional 75 shares in the last quarter. SPC Financial Inc. lifted its stake in shares of iShares Biotechnology ETF by 2.4% in the third quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock valued at $475,000 after buying an additional 75 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its stake in shares of iShares Biotechnology ETF by 2.7% in the third quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after buying an additional 76 shares in the last quarter. Finally, Main Street Financial Solutions LLC lifted its stake in shares of iShares Biotechnology ETF by 1.0% in the second quarter. Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock valued at $1,098,000 after buying an additional 82 shares in the last quarter. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Down 0.3 %
iShares Biotechnology ETF stock opened at $133.04 on Tuesday. iShares Biotechnology ETF has a 1-year low of $117.28 and a 1-year high of $150.57. The firm’s fifty day moving average price is $144.26 and its two-hundred day moving average price is $141.80.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- What is a Bond Market Holiday? How to Invest and Trade
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What is the Australian Securities Exchange (ASX)
- Applied Materials Market Capitulates: Now is the Time to Buy
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.